Healthcare
Reviva Pharmaceuticals Holdings, Inc.(RVPH)
Live Price
Offline$0.6839
-10.01% today
1Y Change
-94.93%
Window
Jun 23, 2025 β Jun 15, 2026
- Market Cap
- β
- Revenue Growth
- 0.0%
- EPS Growth
- +69.6%
- Dividend Yield
- 0.0%
Coverage: 247 bars Β· Jun 23, 2025 β Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Reviva Pharmaceuticals Holdings, Inc. (RVPH) is a Healthcare stock with listed on NASDAQ. The stock last traded around $0.68 and down 94.9% across the available one-year price window (Jun 23, 2025 β Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +69.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +69.6%, free cash flow -73320626.8% with operating margin 0.0% and ROIC -223.1%. Stock Foundry combines RVPH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 21, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +69.6%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.4% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 21, 2026 | β | -1.5% | +3.2% | β |
2026 Mar 30, 2026 | +33.3% | +10.6% | +18.2% | +33.3% |
2025 Nov 13, 2025 | +45.5% | -7.4% | -11.1% | +24.1% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RVPH
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
RVPH Max Drawdown
-98.02%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RVPH and SPY.
Company Overview
Reviva Pharmaceuticals Holdings, Inc.
NASDAQ Capital Market
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentionΒdeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.
- Leadership
- Laxminarayan Bhat
- IPO Date
- Oct 18, 2018
- Employees
- 14
- Street Address
- 19925 Stevens Creek Boulevard
- Mailing
- Cupertino, CA, 95014
- Region
- Cupertino, CA, US
- Reporting Currency
- USD
- Investor Line
- 408 501 8881
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- 0.7
- Price/Sales
- β
- Price/Book
- 0.0
Growth
- Revenue
- 0.0%
- EPS
- +69.6%
- Free Cash Flow
- -73320626.8%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -918.9%
- ROIC
- -223.1%
Balance Sheet
- Debt/Equity
- 0.05
- Current Ratio
- 2.08
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.